Walvax Biotechnology Co Ltd: A Snapshot of Current Performance and Offerings
Walvax Biotechnology Co., Ltd., a prominent player in the biotechnology sector, is a biological pharmaceutical company based in Kunming, China. Established in 2001, the company has carved a niche for itself in the health care industry by focusing on the research, development, production, and sales of bio-medicine products. Walvax is listed on the Shenzhen Stock Exchange and has been a significant contributor to the biotechnology landscape in China.
As of April 28, 2025, Walvax’s stock closed at 9.89 CNY, reflecting a notable fluctuation over the past year. The company’s shares reached a 52-week high of 18.98 CNY on October 8, 2024, and a low of 9.7 CNY on April 6, 2025. With a market capitalization of 16,233,391,658 CNY, Walvax’s financial metrics indicate a price-to-earnings ratio of 124.032, suggesting investor expectations of future growth.
Product Portfolio and Contributions to Public Health
Walvax’s product offerings are diverse, focusing primarily on vaccines that address various infectious diseases. The company’s portfolio includes:
Group A, C meningococcal polysaccharide conjugate vaccine: Designed for infants aged three months to five years, this vaccine aims to prevent diseases such as cerebrospinal meningitis and septicemia caused by Neisseria meningitidis groups A or C.
Group A and C meningococcal polysaccharide vaccine: Targeted at children over two years and adults, this vaccine helps prevent diseases caused by Neisseria meningitidis groups A or C.
Group ACYW135 meningococcal polysaccharide vaccine: For children above two years, this vaccine is intended to prevent meningococcal disease caused by epidemic Neisseria meningitidis groups A, C, Y, and W135.
Haemophilus influenzae type b conjugate vaccine: Available in prefilled syringe dosage form, this vaccine is for infants aged two months to five years, preventing diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis.
Diphtheria, tetanus, and acellular pertussis combined vaccine: This vaccine is for individuals aged three months to six years, preventing diphtheria, tetanus, and pertussis.
23-valent pneumococcal polysaccharide vaccine: Aimed at children above two years, this vaccine helps prevent pneumococcal disease caused by 23 serotypes.
Walvax’s commitment to public health is evident through its extensive range of vaccines, which play a crucial role in preventing infectious diseases across various age groups.
Corporate Overview and Market Presence
Walvax Biotechnology Co., Ltd. has its headquarters in Kunming, China, and maintains an active online presence through its website, www.walvax.com . The company’s initial public offering took place on November 12, 2010, marking its entry into the public market and setting the stage for its growth and expansion in the biotechnology sector.
As a key player in the health care industry, Walvax continues to focus on innovation and development, contributing significantly to the field of bio-medicine in China and beyond. The company’s strategic focus on vaccine development underscores its dedication to enhancing public health and addressing global health challenges.